Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
Aclaris Therapeutics (NASDAQ: ACRS) will present at the 2026 Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 9:35 AM PT. Dr. Hugh Davis, President and COO, will deliver the corporate presentation. A live and archived webcast will be available on the company website for at least 30 days.
Aclaris (NASDAQ: ACRS) reported Q1 2026 results and clinical updates on May 7, 2026. Key clinical highlights include positive Phase 1a SAD/MAD results for bispecific antibody ATI-052 with an estimated half-life ~45 days and sustained PD through week 20 in the 480 mg cohort. The company completed bosakitug Phase 2 enrollment (109 patients) and plans Phase 2b for ATI-052 and an IND for ATI-9494 in H2 2026. Financially, cash and investments totaled $190.8M at March 31, 2026; the company expects runway through end of 2028. Q1 net loss was $19.8M.
Aclaris Therapeutics (NASDAQ: ACRS) reported positive full top-line Phase 1a SAD/MAD results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing an estimated half-life of ~45 days and sustained PD activity supporting up to three-month dosing.
The company also selected lichen planus as the lead indication for oral ITK/JAK3 inhibitor ATI-2138 and plans Phase 2b programs in 2H 2026; Phase 1b ATI-052 trials in asthma and atopic dermatitis have top-line results expected in 2H 2026.
Aclaris Therapeutics (NASDAQ: ACRS) will release full Phase 1a results for its anti-TSLP/IL-4R bispecific antibody ATI-052 and announce lead indication selection for its ITK/JAK3 inhibitor ATI-2138 before markets open on April 28, 2026.
The company will host a webcast and conference call with slides on April 28, 2026 at 8:30 AM EST; the live and archived webcast will be available on the company Events page and archived for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026 at 12:00 PM EDT.
CEO Dr. Neal Walker and senior leaders will join a fireside chat; a live webcast and archived replay will be available on the company website for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) presented Phase 2a ePoster results for oral ATI-2138 at the 2026 AAD meeting showing rapid, sustained improvements in atopic dermatitis measures at week 12.
Key week-12 outcomes for 10 mg BID included EASI -77%, BSA -70%, PP-NRS -50%, POEM -55%, and DLQI -65%, plus near-complete ITK occupancy and multi-pathway modulation.
Aclaris Therapeutics (NASDAQ: ACRS) announced an ePoster presenting previously unreported results from its open-label Phase 2a trial of ATI-2138 for moderate-to-severe atopic dermatitis at the 2026 AAD Annual Meeting in Denver, CO on March 20, 2026.
ATI-2138 is described as an investigational oral covalent inhibitor targeting ITK and JAK3. The poster lists Aclaris and Mount Sinai authors and will be available electronically during the meeting.
Aclaris Therapeutics (NASDAQ: ACRS) completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis, enrolling 109 patients. Top-line results are expected in the fourth quarter of 2026.
The trial's primary endpoint is percent change from baseline in EASI at week 24; secondary endpoints include EASI-50/75/90, IGA, BSA, and PP-NRS. Safety, PD biomarkers, and PK will be assessed. The company cites a 23-day natural half-life and potential dosing convenience as product attributes.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026 at 1:40 PM EDT. CEO Dr. Neal Walker and senior leaders will join a fireside chat. A live and archived webcast will be available on the company Events page for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 and full‑year 2025 results and provided a corporate update highlighting clinical progress across its biologics and oral ITK programs. Key milestones include positive interim Phase 1a SAD/MAD results for ATI‑052, Phase 1b POC trials initiated with top‑line readouts expected H2 2026, an IND filing for ATI‑9494 targeted H2 2026, promising preclinical hair‑regrowth data for ATI‑2138, cash of $151.4M and a stated runway into H2 2028.